相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A year-long extended release nanoformulated cabotegravir prodrug
Tanmay A. Kulkarni et al.
NATURE MATERIALS (2020)
Cabotegravir Plus Rilpivirine: First Approval
A. Markham
DRUGS (2020)
The HIV Reservoir in Monocytes and Macrophages
Michelle E. Wong et al.
FRONTIERS IN IMMUNOLOGY (2019)
Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor
Dario Cattaneo et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
The clinical pharmacology of integrase inhibitors
Giovanni Di Perri et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir
Parul Patel et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States
Kenneth H. Mayer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Tian Zhou et al.
BIOMATERIALS (2018)
Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
Tristan D. McPherson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Martin Markowitz et al.
LANCET HIV (2017)
Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
Ridhi Parasrampuria et al.
Open Forum Infectious Diseases (2017)
HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving
Paul Castellano et al.
SCIENTIFIC REPORTS (2017)
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251
Chasity D. Andrews et al.
AIDS (2017)
Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam
Melinda J. Reese et al.
XENOBIOTICA (2016)
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans
Gary David Bowers et al.
XENOBIOTICA (2016)
The promise and pitfalls of long-acting injectable agents for HIV prevention
Raphael J. Landovitz et al.
CURRENT OPINION IN HIV AND AIDS (2016)
Cabotegravir long-acting for HIV-1 prevention
Chasity D. Andrews et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Formulation and pharmacology of long-acting cabotegravir
Christine Trezza et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus
Chasity D. Andrews et al.
SCIENCE (2014)
Patient preferences for characteristics of antiretroviral therapies: results from five European countries
Brian Gazzard et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2014)
Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
W. Spreen et al.
HIV CLINICAL TRIALS (2013)
Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
Ivy Song et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery
Huanyu Dou et al.
BLOOD (2006)
Impact of an adherence clinic on behavioral outcomes and virologic response in the treatment of HIV infection: A prospective, randomized, controlled pilot study
RC Rathbun et al.
CLINICAL THERAPEUTICS (2005)
Patient adherence to HIV medication regimens: a review of published and abstract reports
L Fogarty et al.
PATIENT EDUCATION AND COUNSELING (2002)
分享论文
